Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study

European Journal of Cancer

Volumn 46, Issue 18, 2010, Pages 3169-3174

  Duffour, Jacqueline ^a   Thézenas, Simon ^a   Dereure, Olivier ^b   Garcin, Agns ^a   Caron, Julie ^b   Samalin, Emmanuelle ^a   Portales, Fabienne ^a   Fiess, Catherine ^a   Chalbos, Patrick ^a   Gestin Boyer, Christine ^a   Ychou, Marc ^a   Guillot, Bernard ^b  

^a CENTRE VAL D AURELLE   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cetuximab; Colorectal cancer; Grading; Rash acne

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ACNE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHELITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; DERMATOLOGY; DESQUAMATION; DRUG DOSE REDUCTION; DRY EYE; EYELID DYSFUNCTION; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; KAPPA STATISTICS; METASTASIS; NAIL; OBSERVATION; ONCOLOGY; PARONYCHIA; PHOTOGRAPHY; PHYSICIAN; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; QUALITATIVE ANALYSIS; RASH; SCABIES; SCORING SYSTEM; SIDE EFFECT; SKIN TOXICITY; TUMOR LOCALIZATION; ULCER; XEROSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL COMPETENCE; COLORECTAL NEOPLASMS; DERMATOLOGY; DRUG ERUPTIONS; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; OBSERVER VARIATION; PILOT PROJECTS;

EID: 78649634429     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.008     Document Type: Article

References (25)

1. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592
2. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
3. H. Wilke, R. Glynne-Jones, and J. Thaler Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study J Clin Oncol 26 2008 5335 5343
4. H.J. Lenz, E. Van Cutsem, and S. Khambata-Ford Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 2006 4914 4921
5. R. Adam, T. Aloia, and F. Levi Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy J Clin Oncol 25 2007 4593 4602
6. B. Gruenberger, D. Tamandl, and J. Schueller Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 2008 1830 1835
7. L.B. Saltz, N.J. Meropol, and P.J. Loehrer Sr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
8. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
9. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
10. M. Mandal, L. Adam, J. Mendelsohn, and R. Kumar Nuclear targeting of Bax during apoptosis in human colorectal cancer cells Oncogene 17 1998 999 1007
11. P. Perrotte, T. Matsumoto, and K. Inoue Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257 265
12. M.C. Prewett, A.T. Hooper, and R. Bassi Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin Cancer Res 8 2002 994 1003
13. W. Jacot, D. Bessis, and E. Jorda Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours Br J Dermatol 151 2004 238 241
14. B. Guillot, and D. Bessis Clinical appearance and management of cutaneous side effects of EGF receptor inhibitors Ann Dermatol Venereol 133 2006 1017 1020
15. National Cancer Institute. Common terminology criteria for adverse events v.3.0; 2006. .
16. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279
17. T.J. Lynch Jr., E.S. Kim, and B. Eaby Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 2007 610 621
18. R. Pérez-Soler, J.P. Delord, and A. Halpern HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncologist 10 2005 345 356
19. N.T. Shah, M.G. Kris, and W. Pao Practical management of patients with non-small-cell lung cancer treated with gefitinib J Clin Oncol 23 2005 165 174
20. M. Purdom Management of acneiform rashes related to gefitinib therapy Clin J Oncol Nurs 8 2004 316 317
21. R.S. Herbst, P.M. LoRusso, M. Purdom, and D. Ward Dermatologic side effects associated with gefitinib therapy: clinical experience and management Clin Lung Cancer 4 2003 366 369
22. S. Segaert, and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 2005 1425 1433
23. A. Scope, A.L. Agero, and S.W. Dusza Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption J Clin Oncol 25 2007 5390 5396
24. A. Jatoi, K. Rowland, and J.A. Sloan Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB) Cancer 113 2008 847 853
25. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357